Physician profile
Frank E Dorn
NPI 1275717191
$4,218.25
in general payments reported to CMS, 2019-2025
33 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $772 · 2024: $1,481 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,218.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $504.06 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.27 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $315.89 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $311.28 | 2025 | Repatha, Otezla, Evenity |
| Braeburn INC. | $296.51 | 2024-2025 | Brixadi |
| Glaxosmithkline, LLC. | $239.97 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $228.09 | 2023-2025 | |
| Lilly USA, LLC | $225.95 | 2023-2025 | Mounjaro, Zepbound |
| Eisai INC. | $198.61 | 2024-2025 | |
| Lundbeck LLC | $182.61 | 2024-2025 | Rexulti, Vyepti |
| Indivior INC. | $146.85 | 2023-2025 | Sublocade |
| Myriad Women'S Health, INC. | $142.50 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.78 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.23 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $97.31 | 2023-2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $90.05 | 2025 | Auvelity |
| Scilex Pharmaceuticals INC. | $83.65 | 2023-2024 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $73.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $62.89 | 2024 | |
| Renalytix Ai, INC. | $52.49 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Daiichi Sankyo INC. | $52.07 | 2024-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $46.80 | 2023-2024 | Spravato |
| Corcept Therapeutics | $37.24 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $34.64 | 2025 | Zoryve |
| Tris Pharma INC | $34.21 | 2024 | Dyanavel Xr |
| Genzyme Corporation | $31.47 | 2025 | |
| Shield Therapeutics INC | $26.80 | 2023 | Accrufer |
| Corium, LLC | $24.16 | 2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.73 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $21.11 | 2025 | Voquezna |
| Exact Sciences Corporation | $16.38 | 2025 | Cologuard Collection Kit |
| Abiomed | $15.53 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Dorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.